BRPI0417341A - glyceguiled factor ix - Google Patents

glyceguiled factor ix

Info

Publication number
BRPI0417341A
BRPI0417341A BRPI0417341-4A BRPI0417341A BRPI0417341A BR PI0417341 A BRPI0417341 A BR PI0417341A BR PI0417341 A BRPI0417341 A BR PI0417341A BR PI0417341 A BRPI0417341 A BR PI0417341A
Authority
BR
Brazil
Prior art keywords
conjugates
factor
glycosyltransferase
peptide
methods
Prior art date
Application number
BRPI0417341-4A
Other languages
Portuguese (pt)
Inventor
Shawn De Frees
Robert J Bayer
Caryn Bowe
Krishnasamy Panneerselvam
Original Assignee
Neose Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neose Technologies Inc filed Critical Neose Technologies Inc
Publication of BRPI0417341A publication Critical patent/BRPI0417341A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FATOR IX GLICOPEGUILADO". A presente invenção proporciona conjugados entre o Fator IX e porções de PEG. Os conjugados são ligados via um grupo de ligação de glicosila intacto interposto entre e covalentemente ligado ao peptídeo e ao grupo de modificação. Os conjugados são formados a partir de peptídeos glicosilados através da ação de uma glicosiltransferase. A glicosiltransferase liga uma porção açúcar modificada a um resíduo de glicosila sobre o peptídeo. Também proporcionados são métodos para o preparo dos conjugados, métodos para o tratamento de várias condições de doença com os conjugados e formulações farmacêuticas incluindo os conjugados."GLICOPEGUILATED FACTOR IX". The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently linked to the peptide and the modifying group. Conjugates are formed from glycosylated peptides through the action of a glycosyltransferase. Glycosyltransferase binds a modified sugar moiety to a glycosyl residue on the peptide. Also provided are methods for the preparation of conjugates, methods for treating various disease conditions with conjugates and pharmaceutical formulations including conjugates.

BRPI0417341-4A 2003-12-03 2004-12-03 glyceguiled factor ix BRPI0417341A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US52708903P 2003-12-03 2003-12-03
US53938704P 2004-01-26 2004-01-26
US59274404P 2004-07-29 2004-07-29
US61451804P 2004-09-29 2004-09-29
US62338704P 2004-10-29 2004-10-29
PCT/US2004/041070 WO2005055950A2 (en) 2003-12-03 2004-12-03 Glycopegylated factor ix

Publications (1)

Publication Number Publication Date
BRPI0417341A true BRPI0417341A (en) 2007-04-17

Family

ID=34682416

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417341-4A BRPI0417341A (en) 2003-12-03 2004-12-03 glyceguiled factor ix

Country Status (10)

Country Link
EP (1) EP1694315A4 (en)
JP (1) JP4738346B2 (en)
KR (1) KR101209111B1 (en)
AU (1) AU2004296860B2 (en)
BR (1) BRPI0417341A (en)
CA (1) CA2549413A1 (en)
IL (1) IL175661A0 (en)
MX (1) MXPA06006023A (en)
NZ (1) NZ546733A (en)
WO (1) WO2005055950A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
AU2004221824B2 (en) 2003-03-14 2009-08-27 Ratiopharm Gmbh Branched water-soluble polymers and their conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
NZ548123A (en) 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
AU2014280936B2 (en) * 2004-06-30 2016-12-15 Nektar Therapeutics Polymer-factor ix moiety conjugates
JP2008505119A (en) 2004-06-30 2008-02-21 ネクター セラピューティクス アラバマ，コーポレイション Macromolecule-Factor IX Conjugate
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20080255026A1 (en) * 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
MX2008002395A (en) * 2005-08-19 2008-03-18 Neose Technologies Inc FACTOR VII AND FACTOR VIIA GLICOPEGILADOS.
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
CN101516388B (en) * 2006-07-21 2012-10-31 诺和诺德公司 Glycosylation of peptides via O-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
WO2008060780A2 (en) * 2006-10-04 2008-05-22 Novo Nordisk A/S Glycerol linked pegylated sugars and glycopeptides
DK2101821T3 (en) 2006-12-15 2014-10-06 Baxter Healthcare Sa Factor VIIA (poly) sialic acid conjugate with extended half-life in vivo
EP2144923B1 (en) 2007-04-03 2013-02-13 BioGeneriX AG Methods of treatment using glycopegylated g-csf
AU2008245524A1 (en) * 2007-04-26 2008-11-06 Cnj Holdings, Inc. Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
AU2008311973B2 (en) * 2007-10-15 2013-10-03 Cangene Corporation Human Factor IX variants with an extended half life
EP2568043A1 (en) * 2007-12-27 2013-03-13 Baxter International Inc. Chemically modified factor IX
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
KR20110005862A (en) * 2008-04-16 2011-01-19 바이엘 헬스케어 엘엘씨 Modified Factor I Polypeptides and Uses thereof
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3081233B1 (en) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
BR112012001814A8 (en) 2009-07-27 2018-02-06 Baxalta GmbH BLOOD COAGULATION PROTEIN CONJUGATIONS
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2744370C2 (en) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Blood coagulation protein conjugates
EA201290069A1 (en) * 2009-07-31 2012-07-30 Байер Хелскер Ллс MODIFIED POLYPEPTIDES OF FACTOR IX AND THEIR APPLICATION
CN107383158A (en) 2009-11-24 2017-11-24 诺沃—诺迪斯克保健股份有限公司 The method for purifying pegylated protein
MX375112B (en) 2010-07-09 2025-03-06 Biogen Hemophilia Inc FACTOR IX POLYPEPTIDES AND METHODS OF USING THEM.
ES2800983T3 (en) 2010-12-22 2021-01-07 Baxalta GmbH Materials and methods for conjugating a water-soluble fatty acid derivative with a protein
TW201519900A (en) * 2013-04-28 2015-06-01 Bayer Healthcare Llc Compositions and methods for inducing immune tolerance to coagulation factor proteins
ES3062513T3 (en) 2019-03-19 2026-04-13 CSL Innovation Pty Ltd Factor ix variants and uses thereof in therapy
WO2026097015A1 (en) 2024-11-01 2026-05-07 Eindura Therapeutics, Inc. Targeted therapeutics with an electrophilic group for covalent attachment and methods of use and manufacture thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (en) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd Novel blood coagulation factor derivative, its preparation and blood coagulation promoting agent containing the same
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (en) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
CA2312843A1 (en) * 1997-12-01 1999-06-10 Neose Technologies Inc. Enzymatic synthesis of gangliosides
EP2292273A3 (en) * 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides

Also Published As

Publication number Publication date
NZ546733A (en) 2009-07-31
EP1694315A2 (en) 2006-08-30
AU2004296860A1 (en) 2005-06-23
CA2549413A1 (en) 2005-06-23
JP2007513190A (en) 2007-05-24
KR101209111B1 (en) 2012-12-06
WO2005055950A3 (en) 2005-10-20
AU2004296860B2 (en) 2010-04-22
EP1694315A4 (en) 2009-10-28
JP4738346B2 (en) 2011-08-03
MXPA06006023A (en) 2006-08-23
IL175661A0 (en) 2006-09-05
WO2005055950A2 (en) 2005-06-23
KR20060123224A (en) 2006-12-01

Similar Documents

Publication Publication Date Title
BRPI0417342A (en) glycopeguylated granulocyte colony stimulating factor
BRPI0614839A2 (en) glycopeguiled factor vii and factor viia
WO2005055950A3 (en) Glycopegylated factor ix
WO2005051327A3 (en) Glycopegylated erythropoietin
FI93227C (en) Use of a carbohydrate compound for the preparation or isolation of viral particles or viral surface components in vitro
WO2006127910A3 (en) Glycopegylated erythropoietin formulations
WO2006127896A3 (en) Glycopegylated factor ix
Zanini et al. Novel Dendritic α-Sialosides: Synthesis of Glycodendrimers Based on a 3, 3 ‘-Iminobis (propylamine) Core
AU729643B2 (en) Polypeptide conjugates for transporting substances across cell membranes
US6030941A (en) Polymer composition for delivering substances in living organisms
WO2006031811A3 (en) Glycopegylated interferon alpha
BR0309868A (en) Calicheamicin derivatives conjugate - carrier
WO2005056760A3 (en) Glycopegylated follicle stimulating hormone
YU48703A (en) New interferon beta-like molecules
BRPI0513959A (en) antibodies directed against beta-amyloid peptide, their pharmaceutical compositions, kit and methods of manufacture thereof
BR0010612A (en) Vaccines
WO2005030258A3 (en) Small molecule compositions and methods for increasing drug efficiency using compositions thereof
DE50014571D1 (en) VEHICLE PHARMAKA CONJUGATES
BRPI0516284A (en) cysteine-constructed antibody, method of selecting antibodies, drug-antibody conjugated compounds, pharmaceutical composition, method for killing or inhibiting tumor cell proliferation, methods of inhibiting cell proliferation and tumor cell growth, manufactured article and method to produce a compound
WO2005051429A2 (en) Targeted conjugates with a modified saccharide linker
BRPI0412671A (en) conjugates of a polymer and a protein linked by an oxime linking group
Shin et al. Chemoselective ligation of maleimidosugars to peptides/protein for the preparation of neoglycopeptides/neoglycoprotein
US11730786B2 (en) High molecular weight polysaccharide that binds and inhibits virus
AU2025242163A1 (en) Saponin derivatives with improved therapeutic window
BR9913446A (en) Aglycone Products and Methods of Use

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NOVO NORDISK A/S (DK)

Free format text: TRANSFERIDO DE: NEOSE TECHNOLOGIES, INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B10A Cessation: cessation confirmed